Difference Between the Profiles Presented by Yeasts that Colonize the Vaginal Mucosa or Cause Primary or Recurrent Candidiasis

Moreira, Débora Astoni; Ruiz, L.S.; Leite-Jr, Diniz Pereira; Auler, Marcos Ereno; Ramos, Renata Pereira; Costa, V T; Lara, Bruna Rossini; Gasparetto, André; Gandra, Rinaldo Ferreira; Melhem, M. S. C.; Paula, Claudete Rodrigues

doi:10.1007/s11046-021-00556-y

Cited by 11 publications

(13 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The portions of NAC species in VVC cases have been reported as 41.4% (n = 87) in Ethiopia (24) and 10%-30% in one other study (25). Furthermore, our result was comparable with the previous observation, in which the presence of a burning sensation is reported in women with C. glabrata and itching with C. albicans infections (19).…”

Section: Discussionsupporting

confidence: 92%

“…Since C. albicans has been found to remain in the vagina between clinical episodes (17), TABLE 4 The in vitro antifungal susceptibility of NAC isolated from patients with RVVC or VVC to eight antifungal drugs. The NAC (non-albicans Candida) species have recently sparked scientific and epidemiological interest as their prevalence keeps increasing globally (19). These NAC species should be a matter of concern during the treatment of RVVC patients due to their propensity for drug resistance (8).…”

Section: Discussionmentioning

confidence: 99%

“…The NAC (non- albicans Candida ) species have recently sparked scientific and epidemiological interest as their prevalence keeps increasing globally ( 19 ). These NAC species should be a matter of concern during the treatment of RVVC patients due to their propensity for drug resistance ( 8 ).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Distinct host immune responses in recurrent vulvovaginal candidiasis and vulvovaginal candidiasis

Yang²,

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Recurrent vulvovaginal candidiasis (RVVC) and vulvovaginal candidiasis (RVVC) are one of the most common gynecological infections, primarily caused by Candida species. Although risk factors of RVVC and VVC have been identified in many studies, antifungal immunological mechanisms are still not fully understood. We performed a 1-year prospective study in a local hospital to monitor 98 patients clinically diagnosed with gynecological Candida infection. The results showed that 20.41% (20/98) are with RVVC, and 79.59% (78/98) patients have VVC. C. albicans accounts for 90% and 96.1% of all strains isolated collected from RVVC and VVC patients, respectively. Antifungal susceptibility testing showed no significant difference in Candida species between RVVC and VVC patients. However, the serum levels of IFN-γ, TNF-α, and IL-17F in the RVVC group were significantly lower than those of the VVC group, while IL-4, IL-6, and IL-10 were higher in the RVVC patients than VVC patients. IL-17A and IL-2 levels were comparable between the two groups. Taken together, our results suggest that the host-immune responses, especially Th1/2 immunity, may play important roles in prognosis of RVVC and VVC.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Distinct host immune responses in recurrent vulvovaginal candidiasis and vulvovaginal candidiasis

Yang²,

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…In this study, we found that the results obtained with cVVC isolates were not statistically significant, different from the results obtained with sVVC isolates, which illustrates the importance of these virulence factors to the immunopathogenicity of vulvovaginal Candida albicans isolates as a whole, as already described [ 5 ]. Recent reports focusing on isolates from different clinical origins involved in vulvovaginal candidosis reached the same conclusions [ 11 , 17 ].…”

Section: Discussionmentioning

confidence: 56%

Vulvovaginal Candida albicans Clinical Isolates’ Resistance to Phagocytosis In-Vitro

Faria-Gonçalves

Oliveira

Gaspar

et al. 2022

Life

View full text Add to dashboard Cite

Previous studies have revealed that Candida albicans isolates involved in chronic vulvovaginal candidosis (cVVC) phenotypically express less virulent traits than clinical isolates involved in sporadic infections. In this study, we aimed to further explore this finding by studying the behaviour of those same clinical isolates in in-vitro models of infection. Eighteen clinical Candida albicans isolates were collected from women suffering sporadic (eight isolates) or chronic infections (ten isolates). Adhesion to HeLa cells (human cervical cancer epithelial cell line) and resistance to phagocytosis by RAW 264.7 cells (murine macrophages cell line) were tested in-vitro. In addition, phenotypic expression of virulence factors related with either adhesion or resistance to phagocytosis was tested in-vitro. Results indicated that yeast isolates involved in sporadic infection adhered in a higher proportion of HeLa cells than those of chronic infections, which was related with their ability to produce biofilm (p < 0.05). The ability to evade phagocytosis was related to an elevated production of proteases (p < 0.05) by chronic isolates, while sporadic isolates’ resistance to phagocytosis was related to a higher hydrophobicity of cell walls (p < 0.05). We conclude that the evasion of macrophage-mediated phagocytosis related to the production of proteases might be an important factor involved in the recurrence of vulvovaginal candidosis infection.

show abstract

“…is the most common [2]. Yeasts have recently been identified as a significant source of vaginal infections in both the community and the hospital, candidiasis of the vulvovaginal tract, also known as VV candidiasis, is the second most common infection of the female genital tract, accounting for nearly 25% of all infectious diseases vaginitis [3][4]. VV candidiasis is a reasonably common infection that affects more than half of all women at some point in their life; of those who have had VV candidiasis, approximately 40-50 % experience further bouts of the infection [5].…”

Section: Introductionmentioning

confidence: 99%

Detection of Candida Spp. That Causes Vulvovaginitis in Women That Use Contraceptive Methods

Alsudani

Al-Awsi²

2022

Wiad Lek

View full text Add to dashboard Cite

The aim: To determine the distribution of Candida spp. within different age groups and contraceptive methods in women with vulvovaginitis, as well as the susceptibility of Candida spp. to commonly used antifungals. Materials and methods: High vaginal swabs were taken from 98 women aged 18 to 50 with vulvovaginitis who used contraceptives and attended the Women and Children Hospital in Al-Diwaniyah; after diagnosis of Candida species, the sensitivity of Candida spp. to some antifungals was studied. Results: The results showed (43/98) women (43.87%) used IUD, (15/98) women (15.30%) used birth control pills, (7/98) women (7.14%) used an injection of contraceptive, (5/98) women (5.10%) used contraceptive suppositories, and (28/98) women (28.57%) did not use any contraceptives. Candida spp. was found in (48/83) specimens (57.831%) from women who used contraceptives and only (11/28) specimens (39.285%) from women who did not use contraceptives. Only (59/98) vaginal specimens tested positive for vaginal candidiasis, (28/59) isolates (47.457%) for C. albicans, then (16/59) isolates for C. glabrata (27.118%), (9/59) isolates (15.254%) for C. tropicalis and (6/59) isolates (10.169%) for C. krusei. Nystatin was the best treatment for all Candida spp. under study, and the MIC was 6.25, and the MFC was 50 for all antifungals and Candida species under study. Conclusions: C. albicans was the most prevalent cause of vulvovaginal candidiasis, while C. glabrata was the most common non-albicans species in women aged 26 to 35; using an IUD was associated with an increased infection of vulvovaginal candidiasis, and nystatin was the most effective treatment.

show abstract

Difference Between the Profiles Presented by Yeasts that Colonize the Vaginal Mucosa or Cause Primary or Recurrent Candidiasis

Cited by 11 publications

References 29 publications

Distinct host immune responses in recurrent vulvovaginal candidiasis and vulvovaginal candidiasis

Distinct host immune responses in recurrent vulvovaginal candidiasis and vulvovaginal candidiasis

Vulvovaginal Candida albicans Clinical Isolates’ Resistance to Phagocytosis In-Vitro

Detection of Candida Spp. That Causes Vulvovaginitis in Women That Use Contraceptive Methods

Contact Info

Product

Resources

About